| Literature DB >> 22885522 |
Thomas R Webb1, Amanda S Joyner, Philip M Potter.
Abstract
The identification of potent spliceosome modulators that demonstrate antitumor activity indicates that this complex may be a target for drug development. Several natural products have been demonstrated to bind to the SF3b1 subunit of this macromolecule and these agents modulate alternative RNA splicing. In this article we describe their biological properties, discuss the validity of the spliceosome as a therapeutic target, and propose that alteration of alternative splicing represents a viable approach for inducing tumor-selective cytotoxicity.Entities:
Mesh：
Substances：
Year: 2012 PMID： 22885522 PMCID： PMC3596818 DOI： 10.1016/j.drudis.2012.07.013
Source DB: PubMed Journal: Drug Discov Today ISSN： 1359-6446 Impact factor: 7.851